1. Home
  2. FF vs ADAG Comparison

FF vs ADAG Comparison

Compare FF & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo FutureFuel Corp.

FF

FutureFuel Corp.

N/A

Current Price

$2.97

Market Cap

223.7M

Sector

Industrials

ML Signal

N/A

Logo Adagene Inc.

ADAG

Adagene Inc.

N/A

Current Price

$1.79

Market Cap

222.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FF
ADAG
Founded
N/A
2011
Country
United States
China
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
223.7M
222.2M
IPO Year
2005
2020

Fundamental Metrics

Financial Performance
Metric
FF
ADAG
Price
$2.97
$1.79
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
★ $9.91
AVG Volume (30 Days)
★ 943.4K
196.5K
Earning Date
11-09-2026
08-12-2026
Dividend Yield
★ 1.41%
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$129.59
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.62
$1.50
52 Week High
$6.99
$4.85

Technical Indicators

Market Signals
Indicator
FF
ADAG
Relative Strength Index (RSI) 16.93 32.03
Support Level N/A N/A
Resistance Level $4.62 $3.50
Average True Range (ATR) 0.30 0.26
MACD -0.34 -0.03
Stochastic Oscillator 9.80 4.92

Price Performance

Historical Comparison
FF
ADAG

About FF FutureFuel Corp.

FutureFuel Corp makes and sells diversified chemical products, bio-based fuel products, and specialty chemical products. The company is organized into two segments based on product type: biofuels and chemicals. The biofuels segment sells biodiesel and other petroleum products, with fuels made from a mix of diesel, vegetable oils, and grease feedstock. The chemicals segment, which generates the majority of revenue, sells products used in the production of agricultural chemicals, including herbicides, as well as coatings and cleaning products such as detergents.

About ADAG Adagene Inc.

Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.

Share on Social Networks: